CytoDyn (CYDY) Non-Current Debt (2012 - 2023)

CytoDyn (CYDY) posted Non-Current Debt of $714000.0 for Q2 2023, up 32.22% on a QoQ basis from $540000.0 in Q2 2014.

CytoDyn (CYDY) Non-Current Debt (2012 - 2023) Analysis & Trends

CytoDyn's Non-Current Debt history runs 4 years deep, the most recent figure standing at $714000.0 for Q2 2023.

Quarterly Non-Current Debt changed N/A year-over-year to $714000.0 in Q2 2023, while the trailing twelve-month figure through May 2023 was $714000.0 (changed N/A YoY) and the FY2023 annual result came in at $714000.0, changed N/A from the prior year.
Non-Current Debt was $714000.0 for Q2 2023 at CytoDyn, up from $540000.0 in the prior quarter.
Across five years, Non-Current Debt topped out at $714000.0 in Q2 2023 and bottomed at $714000.0 in Q2 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Debt (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	105.94 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	842.92 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	1.99 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	CytoDyn	267.79 Mn	267.79 Mn	-	-

Download Data